Attached files

file filename
10-Q - 10-Q - OPIANT PHARMACEUTICALS, INC.v412674_10q.htm
EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC.v412674_ex31-1.htm
EX-10.2 - EXHIBIT 10.2 - OPIANT PHARMACEUTICALS, INC.v412674_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - OPIANT PHARMACEUTICALS, INC.v412674_ex10-1.htm
EXCEL - IDEA: XBRL DOCUMENT - OPIANT PHARMACEUTICALS, INC.Financial_Report.xls
EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC.v412674_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - OPIANT PHARMACEUTICALS, INC.v412674_ex32-1.htm

 

 EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Lightlake Therapeutics Inc. (the “Company") for the period ended April 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Kevin Pollack as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 12, 2015

 

  By:   /s/ Kevin Pollack  
  Kevin Pollack  
 

Chief Financial Officer

(Principal Financial and Accounting Officer)